한글목차

세계의 정맥 철분 주사제 시장 규모는 2024년에 24억 6,000만 달러로 평가되었고, 2030년에는 33억 9,000만 달러에 이를 것으로 예측되며, CAGR은 5.70%를 나타낼 전망입니다.

정맥 철분 주사제 요법은 경구 철 보충제를 견딜 수 없거나 충분한 효과를 얻지 못한 환자에게 중요한 선택으로 부상했습니다.

만성 신장병(CKD), 염증성 장질환(IBD), 심부전, 암 등의 만성 질환과 관련된 빈혈의 만연이 수요를 밀어 올리는 주요 요인이 되고 있습니다. 이러한 진보와 의료 전문가의 의식이 높아져, 선진국·개발도상국 쌍방의 의료 시스템에 있어서, 정맥 철분 주사제 요법의 매력과 접근성이 높아지고 있습니다.

주요 시장 성장 촉진요인

건강 관리 산업의 성장

주요 시장 과제

치료비 급등

주요 시장 동향

모자 보건에 대한 관심 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 정맥 철분 주사제 시장에 미치는 영향

제5장 세계의 정맥 철분 주사제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율·예측
  • 제품별(철 덱스트란, 글루콘산 철, 자당, 철 카르복시말토스, 철 이소말토사이드 1000, 페루목시톨)
  • 용도별(장 흡수 장애 증후군, 염증성 질환, 위 절제술/바리트릭 수술, 빈혈, 오시에-베버-렌두병, 혈관 이형성증, 임신, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 정맥 철분 주사제 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 정맥 철분 주사제 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 정맥 철분 주사제 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 정맥 철분 주사제 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 정맥 철분 주사제 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병과 인수
• 제품 출시
• 최근 동향

제13장 혼란 : 분쟁, 유행, 무역 장벽

제14장 세계의 정맥 철분 주사제 시장 : SWOT 분석

제15장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제16장 경쟁 구도

• AMAG pharmaceuticals, Inc.
• Vifor Pharma Management Ltd.
• Daiichi Sankyo Company, Limited
• Rockwell Medical Inc.
• Allergan PLC
• Pfizer Inc.
• Nippon Shinyaku Co.
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.

제17장 전략적 제안

제18장 기업 소개와 면책사항

영문목차

The Global Intravenous Iron Drugs Market was valued at USD 2.46 Billion in 2024 and is projected to reach USD 3.39 Billion by 2030, registering a CAGR of 5.70%. Intravenous (IV) iron therapy has emerged as a critical alternative for patients who cannot tolerate or respond inadequately to oral iron supplements. This approach is gaining prominence in hospital settings, oncology departments, and dialysis centers where rapid iron restoration is essential.

The growing prevalence of anemia related to chronic conditions such as chronic kidney disease (CKD), inflammatory bowel disease (IBD), heart failure, and cancer is a major factor propelling demand. The introduction of safer, next-generation IV iron formulations has also improved clinical adoption by reducing adverse reactions and eliminating the need for test dosing. These advancements, combined with increasing awareness among healthcare professionals, are enhancing the appeal and accessibility of IV iron therapy in both developed and developing healthcare systems.

Key Market Drivers

Growth in Healthcare Industry

The rapid growth of the global healthcare sector continues to be a fundamental driver of the intravenous iron drugs market. With annual revenues exceeding USD 4 trillion, the healthcare industry includes key segments like pharmaceuticals, biotechnology, and diagnostics-each contributing significantly to the expansion of IV therapies.

Chronic diseases such as CKD, IBD, and cancer are increasingly diagnosed and treated as healthcare infrastructure improves globally. This has elevated the demand for iron supplementation, particularly in cases of iron-deficiency anemia that require immediate and effective intervention. By 2026, the number of hospitals worldwide is projected to reach 215,977, driven primarily by growth in regions like China, the Far East, and parts of Africa and the Middle East. With rising numbers of specialty clinics, diagnostic centers, and infusion-equipped facilities, the uptake of IV iron therapies is becoming more widespread, further fueling market momentum.

Key Market Challenges

High Cost of Treatment

A major hurdle facing the intravenous iron drugs market is the relatively high cost of treatment. Newer formulations such as ferric carboxymaltose and iron isomaltoside entail higher costs than conventional oral supplements. These expenses encompass drug prices, administration services, medical staff, and monitoring post-infusion, especially in hospital or clinic settings.

This cost factor poses a significant barrier in resource-limited countries where public health budgets are constrained. Even in advanced healthcare systems, variations in insurance coverage and high out-of-pocket costs can impede access to IV iron therapies. These economic barriers restrict wider adoption and make cost-containment strategies critical to expanding market reach.

Key Market Trends

Increasing Focus on Maternal and Pediatric Health

A notable trend influencing the intravenous iron drugs market is the growing emphasis on improving maternal and pediatric health outcomes. Iron-deficiency anemia remains prevalent among pregnant women and children, particularly in low- and middle-income countries. Sub-Saharan Africa alone accounts for roughly 70% of global maternal deaths, underlining the urgent need for effective interventions.

IV iron therapy is increasingly recognized as a preferred treatment for moderate to severe anemia during pregnancy, especially when oral supplements prove ineffective. Timely administration helps reduce the risk of complications such as low birth weight, preterm labor, and postpartum hemorrhage. This trend is supported by heightened awareness among healthcare professionals and the inclusion of IV iron in prenatal care protocols, signaling continued market growth in this segment.

Key Market Players

• AMAG Pharmaceuticals, Inc.
• Vifor Pharma Management Ltd.
• Daiichi Sankyo Company, Limited
• Rockwell Medical Inc.
• Allergan PLC
• Pfizer Inc.
• Nippon Shinyaku Co.
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.

Report Scope

In this report, the Global Intravenous Iron Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intravenous Iron Drugs Market, By Product:

• Iron Dextran
• Ferric Gluconate
• Iron Sucrose
• Ferric Carboxymaltose
• Iron Isomaltoside 1000
• Ferumoxytol

Intravenous Iron Drugs Market, By Application:

• Intestinal Malabsorption Syndromes
• Inflammatory Diseases
• Gastrectomy/Bariatric Surgery
• Anemia
• Osier-Weber-Rendu Disease
• Angiodysplasia
• Pregnancy
• Others

Intravenous Iron Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Iron Drugs Market.

Available Customizations

Global Intravenous Iron Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Intravenous Iron Drugs Market

5. Global Intravenous Iron Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxymaltos, Iron Isomaltoside 1000, Ferumoxytol)
  • 5.2.2. By Application (Intestinal Malabsorption Syndromes, Inflammatory Diseases, Gastrectomy/Bariatric Surgery, Anemia, Osier-Weber-Rendu Disease, Angiodysplasia, Pregnancy, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Intravenous Iron Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Intravenous Iron Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Intravenous Iron Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Intravenous Iron Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Intravenous Iron Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Intravenous Iron Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Intravenous Iron Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Intravenous Iron Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Intravenous Iron Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Intravenous Iron Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia Pacific Intravenous Iron Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Intravenous Iron Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Intravenous Iron Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Intravenous Iron Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Intravenous Iron Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Intravenous Iron Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. South America Intravenous Iron Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Intravenous Iron Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Intravenous Iron Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Intravenous Iron Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. Middle East and Africa Intravenous Iron Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Intravenous Iron Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Intravenous Iron Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Intravenous Iron Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Intravenous Iron Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. AMAG pharmaceuticals, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Vifor Pharma Management Ltd.
• 16.3. Daiichi Sankyo Company, Limited
• 16.4. Rockwell Medical Inc.
• 16.5. Allergan PLC
• 16.6. Pfizer Inc.
• 16.7. Nippon Shinyaku Co.
• 16.8. Novartis International AG
• 16.9. Takeda Pharmaceutical Company Limited
• 16.10. Bausch Health Companies Inc.

17. Strategic Recommendations

18. About Us & Disclaimer